Message from the Chairman

Dear Partners and Stakeholders Committed to Medigen’s Sustainable Development,
The year 2024 represents a significant milestone as Medigen embarks on a new phase of sustainable growth. As a leading biotechnology company, Medigen not only advances with determination in innovation, research and development, and international expansion, but also fully recognizes the critical importance of corporate responsibility. Medigen recognizes that enduring and stable growth can only be realized through the full integration of environmental protection, social responsibility, and sound corporate governance into every dimension of its development.

Over the past year, Medigen has leveraged Taiwan’s strengths in biotechnology R&D in combination with its extensive international clinical development expertise. We have deepened strategic alliances with Japanese pharmaceutical partners, secured exclusive sales rights in Taiwan, and are jointly preparing to expand into high-potential Asian markets — steps that further enhance our competitiveness in the global biotechnology and healthcare landscape. Guided by our philosophy, “Innovations for a Better Life,” Medigen remains committed to addressing unmet medical needs by focusing on a range of innovative and emerging therapeutic approaches, including small molecule drugs, oncolytic virus therapies, and immune cell treatments. These efforts aim to deliver more accessible treatment options to patients worldwide.

In the area of environmental sustainability, Medigen actively implements initiatives such as energy conservation, carbon emission reduction, and resource recycling, striving to minimize our environmental footprint across operations. While our core activities center on biotechnology R&D — which entails relatively limited direct environmental impact — we continue to strengthen internal management, promote energy efficiency, adopt green office practices, implement electronic approval systems, and enhance waste reduction and recycling programs.

Medigen also places great emphasis on fulfilling its social responsibilities. We provide comprehensive employee benefits, ensuring that every team member can develop and thrive in a safe and healthy work environment. In alignment with international human rights conventions, we maintain fair and equitable employment policies and are committed to fostering a workplace free from discrimination. Moreover, we encourage employee engagement in charitable initiatives — such as material donations and receipt collection drives — to extend care and assistance to rural and underserved communities.

We regard corporate governance as the cornerstone of sustainable development. Through robust risk management frameworks and procedures, we effectively identify and mitigate potential risks while ensuring operational transparency and financial soundness. Sustainability performance is reported to the Board of Directors on a regular basis, ensuring that Medigen’s sustainability objectives and strategies are continually reviewed and refined.

Looking ahead, Medigen will continue to embrace sustainability as its guiding principle, strengthening our leadership position within the biotechnology industry. We remain dedicated to advancing technological innovation, enhancing product quality, and working in close partnership with our colleagues and stakeholders to actively uphold our environmental and social commitments.